Flagship Biosciences partners with Genomenon for biomarker discovery
BROOMFIELD — Flagship Biosciences Inc., a Broomfield-based spatial-biology company, has formed a strategic partnership with Genomenon Inc., based in Ann Arbor, Michigan, to accelerate biomarker discovery and development of companion diagnostics.
Financial terms of the deal were not disclosed.
Genomenon will provide disease-specific genomic datasets to assist Flagship in assay development, validation and implementation for drug trials, biomarker discovery development of companion diagnostics..
Flagship last year acquired Interpace Pharma Solutions, giving it access to cytogenetic, molecular pathology and genomic profiling technologies. The partnership with Genomenon will further bolster the company’s strength in genomic profiling, according to a press release.
“By leveraging Genomenon’s cutting-edge technology and expertise, we will be able to deliver genomic profiling services that are even more precise, providing unparalleled insights into biomarker characterization and optimal patient stratification for clinical trials and treatment selection,” Flagship Biosciences CEO Trevor Johnson said in a statement.
“Through this partnership, Genomenon will enable the Flagship scientific team to provide their customers with extensive, previously unidentified variant information, giving patients quicker access to life-saving treatments,” said Genomenon CEO Mike Klein.
Flagship Biosciences offers spatial biology services, using artificial-intelligence image-analysis technology that improves the accuracy of tissue-based pathology by delivering thousands of measurements on every cell and enabling the discovery of biomarkers that might be missed using traditional histology methods. The services are used to support drug trials, biomarker discovery and clinical diagnostics.